BRPI0923192A2 - tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2 - Google Patents

tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2

Info

Publication number
BRPI0923192A2
BRPI0923192A2 BRPI0923192A BRPI0923192A BRPI0923192A2 BR PI0923192 A2 BRPI0923192 A2 BR PI0923192A2 BR PI0923192 A BRPI0923192 A BR PI0923192A BR PI0923192 A BRPI0923192 A BR PI0923192A BR PI0923192 A2 BRPI0923192 A2 BR PI0923192A2
Authority
BR
Brazil
Prior art keywords
spla2
inhibitors
treatment
combination therapies
acute coronary
Prior art date
Application number
BRPI0923192A
Other languages
English (en)
Inventor
Hislop Colin
Odink Debra
Trias Joaquim
Truex Paul
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of BRPI0923192A2 publication Critical patent/BRPI0923192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0923192A 2008-12-19 2009-12-18 tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2 BRPI0923192A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13940008P 2008-12-19 2008-12-19
US17442309P 2009-04-30 2009-04-30
US23996709P 2009-09-04 2009-09-04
PCT/US2009/068869 WO2010071854A1 (en) 2008-12-19 2009-12-18 Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
BRPI0923192A2 true BRPI0923192A2 (pt) 2017-03-28

Family

ID=42267026

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923192A BRPI0923192A2 (pt) 2008-12-19 2009-12-18 tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2

Country Status (13)

Country Link
US (1) US20100160361A1 (pt)
EP (1) EP2393358A1 (pt)
JP (1) JP2012512908A (pt)
KR (1) KR20110103428A (pt)
CN (1) CN102325449A (pt)
AU (1) AU2009327374A1 (pt)
BR (1) BRPI0923192A2 (pt)
CA (1) CA2747557A1 (pt)
CR (1) CR20110290A (pt)
EA (1) EA201170848A1 (pt)
IL (1) IL212990A0 (pt)
MX (1) MX2011006545A (pt)
WO (1) WO2010071854A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939287B2 (en) * 2008-05-14 2011-05-10 The Regents Of The University Of California Methods of identifying a subject having or at risk of having or developing coronary artery disease
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472389B1 (en) * 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect
CA2346334A1 (en) * 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
AU1304801A (en) * 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
EP1470240A4 (en) * 2002-02-01 2006-08-30 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
US20030087944A1 (en) * 2002-08-05 2003-05-08 Macias William Louis Method for the treatment of renal dysfunction with spla2 inhibitors
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof

Also Published As

Publication number Publication date
US20100160361A1 (en) 2010-06-24
WO2010071854A1 (en) 2010-06-24
KR20110103428A (ko) 2011-09-20
JP2012512908A (ja) 2012-06-07
IL212990A0 (en) 2011-07-31
CA2747557A1 (en) 2010-06-24
CR20110290A (es) 2011-09-09
CN102325449A (zh) 2012-01-18
AU2009327374A1 (en) 2011-07-07
EP2393358A1 (en) 2011-12-14
MX2011006545A (es) 2011-11-01
EA201170848A1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
EP2434975A4 (en) PLASMA DEVICE FOR PROCESSING LARGE FABRIC SURFACES
EP2590982A4 (en) PROTEIN KINASE INHIBITOR AND TREATMENT PROCEDURE THEREWITH
EP2278969A4 (en) JANUS KINASE INHIBITORS
EP2299816A4 (en) JANUS KINASE INHIBITORS
EA201001860A1 (ru) Ингибиторы дпп-4 для лечения неалкогольной жировой дистрофии печени
EP2166846A4 (en) JANUS KINASE INHIBITORS
EP2231143A4 (en) JANUS KINASE INHIBITORS
EP2310384A4 (en) JANUS KINASE INHIBITORS
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
EP2341775A4 (en) JANUS KINASE INHIBITORS
BRPI0917625A2 (pt) substratos que fornecem liberações multiplas de agentes ativos
EP3685783C0 (en) ENDOLUMINAL LASER ABLATION DEVICE FOR VEIN TREATMENT
EP1926485A4 (en) HIF-INHIBITORS
ATE505460T1 (de) Indazolderivate als inhibitoren der hormon- sensitiven lipase
CR9850A (es) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
EP1973546A4 (en) CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
EP2036552A4 (en) SENESCENCE INHIBITOR
EP2200612A4 (en) JANUS KINASE INHIBITORS
UY31771A1 (es) Inhibidores de catepsina c
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
DE602006018451D1 (de) Hemmer der zytosolen phospholipase a2
EP2124563A4 (en) Benzimidazole TRPV1 INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]